X0508 4 2025-07-08 1 0001711933 Akoya Biosciences, Inc. AKYA 0001857447 McKelligon Brian C/O AKOYA BIOSCIENCES, INC. 100 CAMPUS DRIVE, 6TH FLOOR MARLBOROUGH MA 01752 1 1 0 0 President and CEO 0 Common Stock 2025-07-08 4 J 0 393338 A 813464 D Common Stock 2025-07-08 4 J 0 331090 A 1144554 D Common Stock 2025-07-08 4 F 0 196866 D 947688 D Common Stock 2025-07-08 4 J 0 947688 D 0 D Employee Stock Option (Right to Buy) .3029 2025-07-08 4 J 0 393338 0 D 2027-11-09 Common Stock 393338 0 D Employee Stock Option (Right to Buy) .4427 2025-07-08 4 J 0 331090 0 D 2029-05-02 Common Stock 331090 0 D Employee Stock Option (Right to Buy) 16.12 2025-07-08 4 J 0 241592 0 D 2031-03-24 Common Stock 241592 0 D Employee Stock Option (Right to Buy) 11.88 2025-07-08 4 J 0 160000 0 D 2032-03-23 Common Stock 160000 0 D Employee Stock Option (Right to Buy) 12.30 2025-07-08 4 J 0 160000 0 D 2033-02-23 Common Stock 160000 0 D Employee Stock Option (Right to Buy) 5.35 2025-07-08 4 J 0 175000 0 D 2034-02-22 Common Stock 175000 0 D Cashless exercise of options pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and the Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix. Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price less than the value of the Per Share Merger Consideration (as defined below) was automatically cashless exercised. Disposition of shares pursuant to Merger Agreement. In connection with the terms of the Merger Agreement, each share of common stock of Issuer outstanding on the Closing Date was converted into the right to receive (a) 0.1461 of a share of common stock of Quanterix (the "Per Share Stock Consideration") and (b) $0.38 in cash, without interest (the "Per Share Cash Consideration" and together with the Per Share Stock Consideration, the "Per Share Merger Consideration"). Each of the Per Share Stock Consideration and the Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement. Disposition of options pursuant to the Merger Agreement. Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. /s/ Brian McKelligon 2025-07-10